Ingredients
melted butter 85 gm
chocolate 225 gm
eggs 2
sugar 35 gm( 7 tsp)
almonds and nuts 75 gm or as much as you want chopped
corn starch 30 gm ( 6 tsp)
cocoa pdr 6-7 tsp
potato boiled and mashed 1 big, mine came to a cup
Method
I added butter, used salted butter and grated cooking chocolate about 200 gm, melted in microwave for a minute.
removed, mixed well, till both were well combined, I broke 1 egg at a time and mixed well. Since my eggs were small I used 3 eggs, beating well after each time with a spoon only.
I added sugar, mixed well, next was cocoa pdr, mixed well
Then added mashed potato little at a time, mixing well, once all were well combined, I added corn starch 1 tsp at a time and mixed well. Once all corn starch was mixed, I added chopped nuts
You can bake it in a pre-heated oven at 180 deg. C for about 20 minutes or till done.
I greased small tea cups, added batter till 3/4th kept for a minute, it rose right till top and hubby and self enjoyed it hot yesterday.
Only after hubby ate, I told him that there is no maida, potato was the main ingredient. Being a big fan of potato, it was fine by him. Then sent photos to my kids, they're wondering how I mentioned potato brownie? I said yes, only potato, no all purpose flour/ maida. It would have come to about 8 cup cakes or about 5-6 mug cakes !
My daughter had sent the recipe, actually wanted to bake on our wedding day, was very tired, then both kids said they had cakes, so decided to bake it yesterday.
I was really surprised how it rose without any baking pdr.? It came out soft. I really enjoyed it, today, planning to make it in a mug, as I felt cup was a bit small !
To be frank, it is not my recipe, but I don't go by measurements given, change as I feel like, didn't measure chocolate either, just grated one big chunk that was broken.
I don't know how to copy the photo from my cellphone here to show you all.
In a fight against Covid-19 pandemic, the researchers have found several existing compounds that block replication of the coronavirus (SARS-CoV-2) within human cells grown in the laboratory.
According to the study, published in the journal Cell Research, the inhibitors all demonstrated potent chemical and structural interactions with a viral protein critical to the virus’s ability to proliferate.
“With a rapidly emerging infectious disease like Covid-19, we don’t have time to develop new antiviral drugs from scratch,” said study researcher Yu Chen from the University of South Florida in the US.
“A lot of good drug candidates are already out there as a starting point. But, with new information from studies like ours and current technology, we can help design even better (repurposed) drugs much faster,” Chen added.
The most promising drug candidates – including the USFDA-approved hepatitis C medication boceprevir and an investigational veterinary antiviral drug known as GC-376 – target the SARS-CoV-2 main protease (Mpro).
Mpro is an enzyme that cuts out proteins from a long strand that the virus produces when it invades a human cell.
Without Mpro, the virus cannot replicate and infect new cells.
Mpro represents an attractive target for drug development against Covid-19 because of the enzyme’s essential role in the life cycle of the coronavirus and the absence of a similar protease in humans.
Since people do not have the enzyme, drugs targeting this protein are less likely to cause side effects, they explained.
The research team identified four leading drug candidates as the most potent and specific for fighting Covid-19. These inhibitors rose to the top after screening more than 50 existing protease compounds for potential repurposing.
These are Boceprevir, a drug to treat Hepatitis C, GC-376, an investigational veterinary drug for a deadly strain of coronavirus in cats, which causes feline infectious peritonitis and Calpain inhibitors II and XII, investigated in the past for cancer, neurodegenerative diseases and other conditions, also showed strong antiviral activity.
“All four compounds were superior to other Mpro inhibitors previously identified as suitable to clinically evaluate for treating SARS-CoV-2,” the study author noted.
melted butter 85 gm
chocolate 225 gm
eggs 2
sugar 35 gm( 7 tsp)
almonds and nuts 75 gm or as much as you want chopped
corn starch 30 gm ( 6 tsp)
cocoa pdr 6-7 tsp
potato boiled and mashed 1 big, mine came to a cup
Method
I added butter, used salted butter and grated cooking chocolate about 200 gm, melted in microwave for a minute.
removed, mixed well, till both were well combined, I broke 1 egg at a time and mixed well. Since my eggs were small I used 3 eggs, beating well after each time with a spoon only.
I added sugar, mixed well, next was cocoa pdr, mixed well
Then added mashed potato little at a time, mixing well, once all were well combined, I added corn starch 1 tsp at a time and mixed well. Once all corn starch was mixed, I added chopped nuts
You can bake it in a pre-heated oven at 180 deg. C for about 20 minutes or till done.
I greased small tea cups, added batter till 3/4th kept for a minute, it rose right till top and hubby and self enjoyed it hot yesterday.
Only after hubby ate, I told him that there is no maida, potato was the main ingredient. Being a big fan of potato, it was fine by him. Then sent photos to my kids, they're wondering how I mentioned potato brownie? I said yes, only potato, no all purpose flour/ maida. It would have come to about 8 cup cakes or about 5-6 mug cakes !
My daughter had sent the recipe, actually wanted to bake on our wedding day, was very tired, then both kids said they had cakes, so decided to bake it yesterday.
I was really surprised how it rose without any baking pdr.? It came out soft. I really enjoyed it, today, planning to make it in a mug, as I felt cup was a bit small !
To be frank, it is not my recipe, but I don't go by measurements given, change as I feel like, didn't measure chocolate either, just grated one big chunk that was broken.
I don't know how to copy the photo from my cellphone here to show you all.
In a fight against Covid-19 pandemic, the researchers have found several existing compounds that block replication of the coronavirus (SARS-CoV-2) within human cells grown in the laboratory.
According to the study, published in the journal Cell Research, the inhibitors all demonstrated potent chemical and structural interactions with a viral protein critical to the virus’s ability to proliferate.
“With a rapidly emerging infectious disease like Covid-19, we don’t have time to develop new antiviral drugs from scratch,” said study researcher Yu Chen from the University of South Florida in the US.
“A lot of good drug candidates are already out there as a starting point. But, with new information from studies like ours and current technology, we can help design even better (repurposed) drugs much faster,” Chen added.
The most promising drug candidates – including the USFDA-approved hepatitis C medication boceprevir and an investigational veterinary antiviral drug known as GC-376 – target the SARS-CoV-2 main protease (Mpro).
Mpro is an enzyme that cuts out proteins from a long strand that the virus produces when it invades a human cell.
Without Mpro, the virus cannot replicate and infect new cells.
Mpro represents an attractive target for drug development against Covid-19 because of the enzyme’s essential role in the life cycle of the coronavirus and the absence of a similar protease in humans.
Since people do not have the enzyme, drugs targeting this protein are less likely to cause side effects, they explained.
The research team identified four leading drug candidates as the most potent and specific for fighting Covid-19. These inhibitors rose to the top after screening more than 50 existing protease compounds for potential repurposing.
These are Boceprevir, a drug to treat Hepatitis C, GC-376, an investigational veterinary drug for a deadly strain of coronavirus in cats, which causes feline infectious peritonitis and Calpain inhibitors II and XII, investigated in the past for cancer, neurodegenerative diseases and other conditions, also showed strong antiviral activity.
“All four compounds were superior to other Mpro inhibitors previously identified as suitable to clinically evaluate for treating SARS-CoV-2,” the study author noted.